@article{discovery10205615,
            year = {2025},
       publisher = {American Medical Association},
         journal = {JAMA Oncology},
           month = {February},
            note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.},
           title = {Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer:
the STAMPEDE Phase 3 Randomized Clinical Trial},
        abstract = {We previously reported that abiraterone acetate and prednisolone (hereafter abiraterone) added at initiation of androgen deprivation therapy (ADT) improved survival of metastatic and very high-risk locally advanced prostate cancer and that combining with enzalutamide did not change efficacy.1 Using next-generation sequencing on plasma DNA, we previously showed that genomic alterations of the androgen receptor (AR) gene contribute to resistance to abiraterone or enzalutamide when initiated for metastatic castration-resistant prostate cancer after progression with ADT alone.2 It is unknown whether hormone intensification at start of ADT alters selection of AR alterations within the gene body and/or enhancer region.3},
             url = {https://doi.org/10.1001/jamaoncol.2024.7051},
            issn = {2374-2437},
          author = {Leone, Gianmarco and Orlando, Francesco and Dutey-Magni, Peter and Vainauskas, Osvaldas and Grist, Emily and Ciani, Yari and Lall, Sharanpreet and Thakali, Suparna and Wingate, Anna and Wetterskog, Daniel and Sachdeva, Ashwin and Sydes, Matthew R and McPhail, Neil and Sreenivasan, Thiagarajan and O'Sullivan, Joe M and Clarke, Noel W and Parmar, Mahesh KB and Brown, Louise C and James, Nicholas D and Demichelis, Francesca and Attard, Gerhardt and the STAMPEDE collaborators, {}}
}